Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2004

View Archived Issues

Antares Pharma announces agreement with ProSkelia

BattellePharma now Ventaira Pharmaceuticals

Celltech Group achieves milestone in osteoporosis collaboration with Amgen

Genome Therapeutics and Amgen conclude research agreement

Pierre Fabre presents protein prenyltransferase inhibitors for cancer and other disorders

Almirall Prodesfarma identifies new H1 antagonists with good selectivity profile

Novel orally bioavailable VLA-4 antagonists under study at Elan

BMS scientists claim Eg5 inhibitors and their use in cancer therapy

Chiron expands its phase II program for IL-2 in the treatment of lymphoma

Glycopeptide-cephalosporin conjugates prepared and tested at Theravance

Sanofi-Synthelabo presents beta3-AR agonists for GI disorders and other uses

Allergan claims novel alpha2-AR agonists with potential as analgesic agents

Thios licenses rPSGL-Ig from Wyeth

Medicure looks back at milestone developments

Archemix and Nuvelo enter development agreement for ARC-183

Kemin Pharma develops two new molecules for HCV

Eloxatin approved for first-line treatment of advanced colorectal cancer

BioStratum and Novo Nordisk to develop antibodies to laminin-5 for cancer

Approvable letter for Cipher's fenofibrate formulation

Phase III R-modafinil program progresses towards Q4 NDA filing

MPI-176716 produces tumor regression in animal models of ovarian cancer

Schering-Plough/Pharmacopeia collaborative compound enters clinical trials

New phase I trial for Traficet-EN

Phase II trial confirms icatibant utility in hereditary angioedema

Second pivotal trial of methylnaltrexone for opioid-induced constipation

Namenda available for moderate to severe Alzheimer's disease

Significant improvements reported for tacrolimus ointment in cutaneous lupus erythematosus

Eszopiclone improves sleep onset, maintenance and quality in patients with chronic insomnia

Low-dose DHEA supplements improve endocrine parameters in postmenopausal women

Identification of anthrax lethal factor inhibitors

Novel class of farnesyltransferase inhibitors synthesized by Abbott

Popular Stories

23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
EACR 2025: Immune rewiring in cancer orchestrates tumor microenvironment
BioWorld Science
Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR)...